Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00048659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00048659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Terminated
Start date
Not reported
Completion date
June 30, 2004
Enrollment
Not reported
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-refractory prostate cancer, prostatic neoplasms